Biodexa Pharmaceuticals (BDRX) Depreciation & Amortization - Total (2015 - 2022)
Biodexa Pharmaceuticals' (BDRX) quarterly Depreciation & Amortization - Total came in at $118725.7 in Q3 2022, down 24.72% quarter-over-quarter from $157717.2 in Q4 2021.
Powered by 
Analysis
Biodexa Pharmaceuticals (BDRX) Depreciation & Amortization - Total (2015 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Depreciation & Amortization - Total across 5 years of filings, most recently posting $118725.7 for Q3 2022.
- In Q3 2022, Depreciation & Amortization - Total changed N/A year-over-year to $118725.7; the TTM figure through Sep 2022 stood at $2.5 million (changed N/A YoY), while the FY2024 annual figure was $149558.2, down 15.92% from the prior year.
- Depreciation & Amortization - Total came in at $118725.7 for Q3 2022 at Biodexa Pharmaceuticals, down from $157717.2 in the prior quarter.
- In the past five years, Depreciation & Amortization - Total ranged from a high of $157717.2 in Q4 2021 to a low of $118725.7 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Biodexa Pharmaceuticals | 52.37 Mn | 41.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 14, 2022 | 118,725.70 |
| Dec 31, 2021 | 157,717.24 |
| Dec 31, 2017 | 1.31 Mn |
| Dec 31, 2016 | 959,767.58 |
| Dec 31, 2015 | 760,262.76 |